Neuronata-R Receives Extended Approval in South Korea for ALS Patients with New Clinical Insights
In a significant development for patients battling amyotrophic lateral sclerosis (ALS) in South Korea, the Ministry of Food and Drug Safety (MFDS) has granted ongoing access to Neuronata-R® (lenzumestrocel), a stem cell therapy previously conditionally approved in 2014. This recent approval, finalized in May 2026, permits the therapy to remain available to patients as the developers work on resuming manufacturing and establishing a research presence in the United States.
The clinical backdrop of this decision revolves around the findings from the ALSUMMIT Phase 3 trial (NCT04745299). While the overall results across the full study population did not achieve statistical significance, the subset of patients identified as slow progressors responded positively, reaching the primary endpoint of the Combined Assessment of Function and Survival (CAFS) as well as a secondary endpoint measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Additionally, these patients exhibited an encouraging decline in neurofilament light chain (NfL), a marker renowned for indicating neuronal damage, thus supporting the therapy's potential efficacy in specific groups.
CorestemChemon is actively engaged in ramping up manufacturing capabilities to ensure uninterrupted treatment for patients dependent on Neuronata-R. Simultaneously, they are expanding their footprint within the U.S. regenerative medicine community. By joining the Piedmont Triad Regenerative Medicine Engine—a partnership fostered by the U.S. National Science Foundation (NSF)—CorestemChemon aims to leverage state-of-the-art research resources and build connections conducive to broader regulatory pathways and access to their therapies over time.
Looking ahead, the company is pursuing a Type C meeting with the FDA, intending to file a Biologics License Application (BLA) within the year. This proactive strategy underscores CorestemChemon's commitment not only to South Korean patients but also to prospective patients globally who may seek Neuronata-R as a treatment option in the future. The anticipated resumption of full-scale production early next year will pave the way for international patients, further solidifying the therapy's position as an essential treatment for ALS.
Neuronata-R operates through autologous bone marrow-derived mesenchymal stem cells (MSCs) acquired from patients themselves. Following laboratory cultivation, these MSCs are administered via intrathecal injection. Rather than replicating motor neurons, the therapy is theorized to exert effects via the secretion of beneficial factors. These include anti-inflammatory agents (TGF-β1, IL-4, IL-10) that mitigate neuroinflammation—often a contributing factor to motor neuron damage—and neuroprotective elements (VEGF, BDNF, IGF) that bolster neuronal survival and function.
To date, over 400 patients in South Korea have received Neuronata-R, accumulating a wealth of safety and efficacy data that fuels the therapy's regulatory journey. Notably, Neuronata-R holds Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency, secured in 2018 and 2019, respectively, enhancing its credibility in the fast-evolving landscape of ALS treatments.
In summary, the MFDS decision to extend Neuronata-R's approval reflects a pivotal moment in ALS care, enabling patients to access a therapy that showcases promise, particularly for those in the slow progressor subgroup. It also signals a future where regenerative medicine continues to innovate and provide hope amidst the challenges posed by neurodegenerative conditions.
The clinical backdrop of this decision revolves around the findings from the ALSUMMIT Phase 3 trial (NCT04745299). While the overall results across the full study population did not achieve statistical significance, the subset of patients identified as slow progressors responded positively, reaching the primary endpoint of the Combined Assessment of Function and Survival (CAFS) as well as a secondary endpoint measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Additionally, these patients exhibited an encouraging decline in neurofilament light chain (NfL), a marker renowned for indicating neuronal damage, thus supporting the therapy's potential efficacy in specific groups.
CorestemChemon is actively engaged in ramping up manufacturing capabilities to ensure uninterrupted treatment for patients dependent on Neuronata-R. Simultaneously, they are expanding their footprint within the U.S. regenerative medicine community. By joining the Piedmont Triad Regenerative Medicine Engine—a partnership fostered by the U.S. National Science Foundation (NSF)—CorestemChemon aims to leverage state-of-the-art research resources and build connections conducive to broader regulatory pathways and access to their therapies over time.
Looking ahead, the company is pursuing a Type C meeting with the FDA, intending to file a Biologics License Application (BLA) within the year. This proactive strategy underscores CorestemChemon's commitment not only to South Korean patients but also to prospective patients globally who may seek Neuronata-R as a treatment option in the future. The anticipated resumption of full-scale production early next year will pave the way for international patients, further solidifying the therapy's position as an essential treatment for ALS.
Neuronata-R operates through autologous bone marrow-derived mesenchymal stem cells (MSCs) acquired from patients themselves. Following laboratory cultivation, these MSCs are administered via intrathecal injection. Rather than replicating motor neurons, the therapy is theorized to exert effects via the secretion of beneficial factors. These include anti-inflammatory agents (TGF-β1, IL-4, IL-10) that mitigate neuroinflammation—often a contributing factor to motor neuron damage—and neuroprotective elements (VEGF, BDNF, IGF) that bolster neuronal survival and function.
To date, over 400 patients in South Korea have received Neuronata-R, accumulating a wealth of safety and efficacy data that fuels the therapy's regulatory journey. Notably, Neuronata-R holds Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency, secured in 2018 and 2019, respectively, enhancing its credibility in the fast-evolving landscape of ALS treatments.
In summary, the MFDS decision to extend Neuronata-R's approval reflects a pivotal moment in ALS care, enabling patients to access a therapy that showcases promise, particularly for those in the slow progressor subgroup. It also signals a future where regenerative medicine continues to innovate and provide hope amidst the challenges posed by neurodegenerative conditions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.